[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
September 17, 1997

Bioequivalence of Levothyroxine Preparations: Issues of Science, Publication, and Advertising

Author Affiliations

Yarmouth Port, Mass

JAMA. 1997;278(11):896. doi:10.1001/jama.1997.03550110034019

To the Editor.  —Dr Dong and colleagues,1 obviously trusting and competent scientists, learned the hard way of the need for a consultation when dealing in a different area, ie, the law. It should be universal academic policy that either the institution's or the investigator's lawyer should review any contract before signing. It is the same lesson other colleagues learned the hard way about "hold harmless" clauses.Rather than fear lack of funding from some companies, reputable businesses would welcome work done at institutions of impeccable integrity. As former medical director of a large skin-care company, I was responsible for product safety. If there was a problem with a product, we wanted to know immediately so that (1) it could be corrected, and (2) when claims were made, the industry and the public knew the products were reliable. This is smart business. Suppressing negative information for deceptive profit is, in the xlong run